SEC Contract Filing

Filing Date: 2019-02-20

Document Content:
<DOCUMENT>
<TYPE>EX-10.66
<SEQUENCE>2
<FILENAME>rare-ex1066_2833.htm
<DESCRIPTION>EX-10.66
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rare-ex1066_2833.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.66</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"> RIVERSIDE TECHNOLOGY CENTER </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">THIRD LEASE AMENDMENT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TO THE LEASE BETWEEN </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RIVERTECH ASSOCIATES II LLC AND ULTRAGENYX PHARMACEUTICAL INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Third Lease Amendment (the &#8220;<font style="text-decoration:underline;">Third Lease Amendment</font>&#8221;) entered into effective as&nbsp;&nbsp;the 31<sup style="font-size:85%; vertical-align:top">st</sup> day of December, 2018 by and between <font style="font-weight:bold;">Rivertech Associates II LLC,</font> a Massachusetts limited liability company with a principal address c/o The Abbey Group, 177 Huntington Avenue 24<sup style="font-size:85%; vertical-align:top">th</sup> Floor Boston, Massachusetts 02115 (herein, the &#8220;<font style="text-decoration:underline;">Lessor</font>&#8221;), and <font style="font-weight:bold;">Ultragenyx Pharmaceutical, Inc. </font>a Delaware corporation (as it is the successor and assignee from Dimension Therapeutics, Inc.), with a business address of 60 Leveroni Court, Novato, California 94949 (herein the &#8220;<font style="text-decoration:underline;">Lessee</font>&#8221;); with respect to a certain Lease dated March 11, 2014 (the &#8220;<font style="text-decoration:underline;">Original Lease</font>&#8221;) for certain office and laboratory space in the building at 840 Memorial Drive Cambridge, Massachusetts (the &#8220;<font style="text-decoration:underline;">Building</font>&#8221;); as amended by a certain First Lease Amendment dated October 22, 2014 (the &#8220;<font style="text-decoration:underline;">First Amendment</font>&#8221;), and a Second Lease Amendment dated April 28, 2017 (the &#8220;<font style="text-decoration:underline;">Second Amendment</font>&#8221;); said Original Lease, First Amendment and Second Amendment being collectively referred to herein as the &#8220;<font style="text-decoration:underline;">Existing Lease</font>&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Term under the Existing Lease expires on January 31, 2020 (the &#8220;<font style="text-decoration:underline;">Current Term</font>&#8221;), and the Lessee seeks to extend the Current Term so as to expire on December 31, 2023 (referred to herein as the &#8220;<font style="text-decoration:underline;">Extended Term Termination Date</font>&#8221;, and supplanting that defined Term in the Second Amendment); which period as extended is referred to herein as the &#8220;<font style="text-decoration:underline;">Extended Term</font>&#8221;; and, </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, under the Existing Lease the Lessee leases and occupies approximately 14,949 rentable square feet of space in the Building, consisting of approximately 8,110 rentable square feet of space on the fourth (4th) floor of the Building, and approximately 6,839 rentable square feet of space on the second (2<sup style="font-size:85%; vertical-align:top">nd</sup>) floor of the Building, (the &#8220;<font style="text-decoration:underline;">Existing Premises